Search results

Back
1 - 10 of 254 Search results
 -  08 October 2020

 -  08 October 2020

 Ipsen to present 12 abstracts at the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress taking place jointly with the 35th Congress of the French Society of Physical and Rehabilitation Medicine (SOFMER)

Attachment...

 -  26 March 2020

 -  26 March 2020

Ipsen provides update on palovarotene clinical programs

...

 -  19 May 2020

 -  19 May 2020

Ipsen announces publication of first matching-adjusted indirect comparison of Cabometyx® (cabozantinib) versus regorafenib in advanced hepatocellular carcinoma in Advances in Therapy

Attachment...

 -  23 May 2020

 -  23 May 2020

New surveys show over 80% of patients with spasticity and cervical dystonia treated with botulinum toxin-A experience debilitating symptom recurrence

...

 -  25 March 2020

 -  25 March 2020

Ipsen provides COVID-19 update

Attachment...

 -  22 April 2020

 -  22 April 2020

Ipsen reports solid sales growth in first quarter 2020 with limited COVID-19 impact

Paris (France), 22 April 2020 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced its sales for the first quarter of 2020....

 -  02 July 2020

 -  02 July 2020

Ipsen joins clinical collaboration to evaluate cabozantinib (CABOMETYX®) plus atezolizumab in metastatic non-small cell lung cancer and metastatic castration-resistant prostate cancer

...

 -  14 January 2020

 -  14 January 2020

Ipsen appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical Officer

Attachment...

 -  24 January 2020

 -  24 January 2020

Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria

Attachment...

 -  11 March 2020

 -  11 March 2020

Ipsen data presented during ENETS Annual Conference 2020 capture new patient and healthcare professional insights in the treatment of NETs and acromegaly

Attachment...

1 … 22 23 24 25 26